Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2796237 | 0.91 | HTT (0.54) | HTTCYP1A2SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL29608780 | 0.91 | HTT (0.54) | HTTCYP1A2SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL29484110 | 0.91 | HTT (0.54) | HTTCYP1A2SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL2792830 | 0.91 | HTT (0.54) | HTTCYP1A2SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL242244 | 0.91 | HTT (0.54) | HTTCYP1A2SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL29706163 | 0.91 | HTT (0.54) | HTTCYP1A2SMN1; SMN2RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL8944136 | 0.89 | HTT (0.53) | HTTCYP1A2SMN1; SMN2RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL2999173 | 0.89 | HTT (0.53) | HTTCYP1A2SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1844342 | 0.85 | HTT (0.49) | HTTCYP1A2SMN1; SMN2RAB9AMEN1 | |
| Ethylenediamine SCHEMBL10773019 | 0.83 | HTT (0.48) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250238-A1 | SYSTEM FOR THE COLON DELIVERY OF DRUGS SUBJECT TO ENZYME DEGRADATION AND/OR POORLY ABSORBED IN THE GASTROINTESTINAL TRACT | SANGALLI MARIA EDVIGE | 2011-10-13 | — | — | US | disclosed |
| EP-1965828-A2 | PHARMACEUTICAL FORMULATION FOR INCREASED EPITHELIAL PERMEABILITY OF GLUCOSE-REGULATING PEPTIDE | Nastech Pharmaceutical Company Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007146448-A1 | PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007065156-A2 | PHARMACEUTICAL FORMULATION FOR INCREASED EPITHELIAL PERMEABILITY OF GLUCOSE-REGULATING PEPTIDE | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-07 | — | — | WO | disclosed |